Marginalization, Vulnerability and Economic Dynamics in COVID-19

Abstract COVID-19, caused by the coronavirus family SARS-CoV-2 and declared a pandemic in March 2020, continues to spread. Its enormous and unprecedented impact on our society has evidenced the huge social inequity of our modern society, in which the most vulnerable individuals have been pushed into even worse socioeconomic situations, struggling to survive. As the pandemic continues, we witness the huge suffering of the most marginalized populations around the globe, even in developed, high-income latitudes, such as North America and Europe. That is even worse in low-income regions, such as Brazil, where the public healthcare infrastructure had already been struggling before the pandemic. Cities with even more evident social inequity have been impacted the most, leaving the most socioeconomically disadvantaged ones, such as slum residents and black people, continuously inflating the statistics of COVID-19 sufferers. Poverty, marginalization, and inequity have been well-known risk factors for morbidity and mortality from other diseases. However, COVID-19 has deepened our society's wound. It is up to us to heal it up. If we really care for the others and want to survive as a species, we must fight social inequity.

Tromboembolismo pulmonar: terapia pós-crise / Pulmonary embolism: therapy post-crisis

O principal objetivo do tratamento pós-fase aguda do tromboembolismo pulmonar é a prevenção de recorrência. Os pacientes devem ser estratificados quanto ao risco de recorrência da doença. Há mais de 50 anos os antagonistas da vitamina K são utilizados nessa fase do tratamento. Recentemente surgiram novos anticoagulantes orais que não necessitam de monitorização laboratorial, sendo uma promessa para o manejo mais fácil do tratamento.

The main objective of treatment post-acute phase of pulmonary thromboembolism is prevention of recurrence. Patients should be stratified by risk of disease recurrence. For over fifty years, vitamin K antagonists are used in this phase of treatment. Recently, a new anticoagulants which do not require laboratory monitoring with a promise for an easier handling of the treatment.